MedTrace Logo

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

NCT00117156 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-08-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of six cycles of concurrent fludarabine and rituximab in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma (MZL) or CD5-, CD10-, CD20+ low-grade B cell lymphomas.

Conditions

  • Lymphoma, Non-Hodgkin
  • MALT Lymphoma

Interventions

DRUG

Fludarabine

DRUG

Rituximab

Sponsors & Collaborators

Principal Investigators

  • Jennifer R. Brown, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2008-10-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00117156 on ClinicalTrials.gov